TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14658946

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study: 10359881

Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Terfenadine 120 mg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 25
Study: 8532099

Group type: EXPERIMENTAL
Intervention: Psychoeducational training for medication management, cognitive therapy, and work with relatives' groups
Number of subjects: 191

Group type: COMPARATOR
Intervention: Standard treatment including neuroleptic relapse prevention
Number of subjects: 191
Study: 1952649

Group type: EXPERIMENTAL
Intervention: Nucleus 22‐channel device
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Smith & Nephew Richards Ineraid device
Number of subjects: 82

Group type: COMPARATOR
Intervention: 3M/Vienna intracochlear device
Number of subjects: 82
Study: 7149218

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Neuroleptanaesthesia
Number of subjects: 49
Study: 30939851

Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (60 mg kg‐1 24 h‐¹)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 54
Study: 29771088

Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 1 month
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 2 months
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 3 months
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Omeprazole enteric‐coated capsules (20mg, Bid) for 4 months
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 160
Study: 26917577

Group type: EXPERIMENTAL
Intervention: Metformin therapy (2 g/day for 1 month)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23961951

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site with a single channel varicocele ligation (LESS[sc]‐VL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional transperitoneal laparoscopic varicocele ligation (CTL‐VL)
Number of subjects: 90
Study: 22138866

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (HCHO; 7 g/kg body weight)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Low carbohydrate diet (LCHO; 2 g/kg body weight)
Number of subjects: 10
Study: 20667682

Group type: EXPERIMENTAL
Intervention: Therapeutic Education System (TES)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 28
Study: 17977274

Group type: EXPERIMENTAL
Intervention: Bilateral thalamic deep brain stimulation (DBS)
Number of subjects: 5
Study: 15743362

Group type: EXPERIMENTAL
Intervention: Octreotide 100 microg intravenous bolus followed by a continuous infusion at 250 microg/h
Number of subjects: 42

Group type: COMPARATOR
Intervention: Terlipressin 2 mg intravenous bolus
Number of subjects: 42
Study: 12542199

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg suppository)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 9469362

Group type: EXPERIMENTAL
Intervention: Filgrastim 5 microg/kg/day administered subcutaneously on days 3 through 9 after each BOP and on days 6 through 19 after each VIP, BEP, or EP cycle
Number of subjects: 250

Group type: COMPARATOR
Intervention: Not receiving filgrastim (control group)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Filgrastim
Number of subjects: 250
Study: 7630200

Group type: EXPERIMENTAL
Intervention: Allogeneic transplant in first remission for patients < 40 years old
Number of subjects: 149

Group type: COMPARATOR
Intervention: Chemotherapy alone for patients < 40 years old
Number of subjects: 149
Study: 2118326

Group type: EXPERIMENTAL
Intervention: Cefazolin (1-g doses, three postoperative)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Ceftriaxone (1-g single dose preoperative)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Cefazolin and Ceftriaxone
Number of subjects: 138
Study: 318965

Group type: EXPERIMENTAL
Intervention: 1.0 mg of terbutaline sulfate
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0.5 mg of epinephrine hydrochloride
Number of subjects: 49
Study: 31326778

Group type: EXPERIMENTAL
Intervention: Asserted evidence of effectiveness
Number of subjects: 7058

Group type: EXPERIMENTAL
Intervention: Quantification of policy effectiveness
Number of subjects: 7058

Group type: EXPERIMENTAL
Intervention: Labelling policy
Number of subjects: 7058

Group type: EXPERIMENTAL
Intervention: Availability policy
Number of subjects: 7058

Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 7058

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 7058

Group type: EXPERIMENTAL
Intervention: High-calorie snack food consumption
Number of subjects: 7058

Group type: COMPARATOR
Intervention: Control group (no message)
Number of subjects: 7058
Study: 28341261

Group type: EXPERIMENTAL
Intervention: Occlusive drainage system
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional indirect wet dressing method
Number of subjects: 28
Study: 25453872

Group type: COMPARATOR
Intervention: Conventional antimicrobial susceptibility testing
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Biofilm antimicrobial susceptibility testing
Number of subjects: 39
Study: 23870605

Group type: EXPERIMENTAL
Intervention: Test formulation: Amlodipine orotate 10 mg and valsartan 160 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Reference formulation: Amlodipine besylate 10 mg and valsartan 160 mg
Number of subjects: 50
Study: 20980201

Group type: EXPERIMENTAL
Intervention: Ramipril (ACE inhibitor)
Number of subjects: 31546

Group type: EXPERIMENTAL
Intervention: Telmisartan (Angiotensin-receptor blocker)
Number of subjects: 31546

Group type: EXPERIMENTAL
Intervention: Combination treatment (ramipril + telmisartan)
Number of subjects: 31546

Group type: COMPARATOR
Intervention: Telmisartan
Number of subjects: 31546

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31546
Study: 19165682

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 17464690

Group type: EXPERIMENTAL
Intervention: Haloperidol or risperidone for 8 weeks (exact dosage not specified)
Number of subjects: 16

Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: N/A (FEP group)
Number of subjects: 16
Study: 15099798

Group type: EXPERIMENTAL
Intervention: FUSS model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latent Semantic Analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Similarity metrics derived from Wordnet
Number of subjects: 0
Study: 11299422

Group type: EXPERIMENTAL
Intervention: CABG without cardiopulmonary bypass (CPB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: CABG with cardiopulmonary bypass (CPB)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CABG without CPB
Number of subjects: 20

Group type: COMPARATOR
Intervention: CABG with CPB
Number of subjects: 20
Study: 10211026

Group type: EXPERIMENTAL
Intervention: Thiopental 5 mg kg‐1 (group TH)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1 and propofol 3 mg kg‐1 (group PAH)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 5% Halothane (group HH)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study: 8740606

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Magnesium chloride
Number of subjects: 10
Study: 2180661

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy aimed at near normalization of blood glucose levels
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1441
Study: 6102878

Group type: EXPERIMENTAL
Intervention: Chlormethiazole (384 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30677465

Group type: EXPERIMENTAL
Intervention: Treat-and-extend (T&E) regimen with intravitreal ranibizumab at a dose of 0.5 mg
Number of subjects: 526

Group type: COMPARATOR
Intervention: Monthly dosing regimen with intravitreal ranibizumab at a dose of 0.5 mg
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Treat-and-extend (T&E) regimen
Number of subjects: 526

Group type: COMPARATOR
Intervention: Monthly dosing regimen
Number of subjects: 526
Study: 28605779

Group type: EXPERIMENTAL
Intervention: DAPT (aspirin and clopidogrel) for 24 months
Number of subjects: 1970

Group type: COMPARATOR
Intervention: DAPT (aspirin and clopidogrel) for 6 months
Number of subjects: 1970
Study: 25811946

Group type: EXPERIMENTAL
Intervention: Isomaltulose (ISO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Fructose-Maltodextrin (F:M)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo-flavored water (PL)
Number of subjects: 9
Study: 23400994

Group type: EXPERIMENTAL
Intervention: Cuff inflation technique with silicone-tipped wire reinforced (SWR) ET tube
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cuff inflation technique with polyvinyl chloride (PVC) ET tube
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Cuff inflation technique with wire reinforced (WR) ET tube
Number of subjects: 162

Group type: COMPARATOR
Intervention: Silicone-tipped wire reinforced (SWR) ET tube
Number of subjects: 162
Study: 21334592

Group type: EXPERIMENTAL
Intervention: Short-term culture (Optisol-GS; Bausch & Lomb) at 4 C (group A; n = 37)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Organ culture (Dulbecco Modified Eagle Medium [Biochrom]; CorneaMax Medium [Eurobio]) at 34 C (group B; n = 45)
Number of subjects: 82
Study: 19723755

Group type: EXPERIMENTAL
Intervention: Iodine-131 treatment
Number of subjects: 313

Group type: COMPARATOR
Intervention: Medical treatment (antithyroid drugs)
Number of subjects: 313
Study: 18001249

Group type: EXPERIMENTAL
Intervention: Lidocaine 4%
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Tetracaine 1%
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both substances
Number of subjects: 26
Study: 15103949

Group type: EXPERIMENTAL
Intervention: Flex Plug (FP)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Eagle Plug (EP)
Number of subjects: 37
Study: 11561769

Group type: EXPERIMENTAL
Intervention: FEC (5-fluorouracil, epirubicin, and cyclophosphamide) - 9 cycles with dose escalation
Number of subjects: 105

Group type: COMPARATOR
Intervention: CTCb (3 cycles of FEC followed by high-dose chemotherapy with alkylating agents)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: FEC (5-fluorouracil, epirubicin, and cyclophosphamide)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Left-sided chest irradiation
Number of subjects: 105
Study: 8612853

Group type: EXPERIMENTAL
Intervention: Crossover trials
Number of subjects: 5291

Group type: COMPARATOR
Intervention: Parallel group trials
Number of subjects: 5291
Study: 1593071

Group type: EXPERIMENTAL
Intervention: CooperVision Permaflex Mystique opaque tinted lens
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Wesley-Jessen Durasoft 3 Colors opaque tinted lens
Number of subjects: 22

Group type: COMPARATOR
Intervention: CooperVision CV Classic non-opaque control lens
Number of subjects: 22

Group type: COMPARATOR
Intervention: Wesley-Jessen Durasoft 3 clear lens
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Wesley-Jessen Durasoft 3 opaque lens
Number of subjects: 22
Study: 6689799

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered via extension tube (250 micrograms)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Terbutaline delivered via extension tube (250, 500, and 750 micrograms)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Terbutaline delivered by regular pressurized aerosol device (250, 500, and 750 micrograms)
Number of subjects: 11
Study: 30285589

Group type: EXPERIMENTAL
Intervention: Personal statement evaluation by six experienced internship candidate evaluators
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of personal statements
Number of subjects: 100
Study: 30630803

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Positive ventilation
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combination group (Dexmedetomidine + Continuous Positive Airway Pressure)
Number of subjects: 126
Study: 26614548

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy only
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Total population
Number of subjects: 169
Study: 25348723

Group type: EXPERIMENTAL
Intervention: Standard 30:2 CPR (ST‐CPR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chest compression-only CPR (CO‐CPR)
Number of subjects: 36
Study: 25885506

Group type: EXPERIMENTAL
Intervention: Intravenous 1 g tranexamic acid 20 min before skin incision
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline as placebo (Control)
Number of subjects: 60
Study: 20218943

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene (PTFE) grafts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polyurethane (PVAG) grafts
Number of subjects: 0
Study: 17326028

Group type: EXPERIMENTAL
Intervention: 1-propanol 60% vol/vol (A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2-propanol 70% m/m plus chlorhexidine gluconate 0.5% wt/wt (B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2-propanol 45% wt/wt plus 1-propanol 30% wt/wt plus mecetronium etilsulfate 0.2% wt/wt (C)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 1-propanol 60% vol/vol, unstained (R)
Number of subjects: 24
Study: 16248471

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20g/day for 7 days followed by 10g/day for 21 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 18
Study: 11896865

Group type: EXPERIMENTAL
Intervention: Natural surfactant (Alveofact)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Synthetic surfactant (Exosurf)
Number of subjects: 92
Study: 10097253

Group type: EXPERIMENTAL
Intervention: 33h of fasting
Number of subjects: 11

Group type: COMPARATOR
Intervention: Regular meals (control)
Number of subjects: 11
Study: 7749764

Group type: EXPERIMENTAL
Intervention: OND + DEX
Number of subjects: 33

Group type: COMPARATOR
Intervention: OND
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 33
Study: 2032107

Group type: EXPERIMENTAL
Intervention: Preoperative oral lactulose (n = 35)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Oral sodium deoxycholate (n = 32)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no specific treatment, n = 35)
Number of subjects: 102
Study: 6754509

Group type: EXPERIMENTAL
Intervention: verapamil 120 mg t.d.s.
Number of subjects: 19

Group type: COMPARATOR
Intervention: propranolol 160 mg b.d.
Number of subjects: 19
Study: 30885120

Group type: EXPERIMENTAL
Intervention: Education and self-management intervention for chronic headache, delivered over two days.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Education and self-management intervention for chronic headache, refined based on pilot feedback.
Number of subjects: 18
Study: 27838190

Group type: EXPERIMENTAL
Intervention: Hormonal therapy with vigabatrin
Number of subjects: 377

Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 377
Study: 26885881

Group type: EXPERIMENTAL
Intervention: 50 mg DHEA (women)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 75 mg DHEA (men)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 5 mg T (men)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (women)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo (men)
Number of subjects: 152
Study: 24439640

Group type: EXPERIMENTAL
Intervention: Reiki therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sham Reiki (control)
Number of subjects: 38
Study: 22157811

Group type: EXPERIMENTAL
Intervention: Motor control training program (15-week intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motor control training program (8-week intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control (7-week intervention)
Number of subjects: 0
Study: 19649513

Group type: EXPERIMENTAL
Intervention: Chest physician support
Number of subjects: 868

Group type: EXPERIMENTAL
Intervention: Software support
Number of subjects: 868

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 868
Study: 17457187

Group type: EXPERIMENTAL
Intervention: Conjunctival limbal autograft (group 1)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Amniotic membrane transplantation (AMT) (group 2)
Number of subjects: 78
Study: 15180336

Group type: EXPERIMENTAL
Intervention: HPMC capsules
Number of subjects: 11

Group type: COMPARATOR
Intervention: Gelatin capsules
Number of subjects: 11
Study: 11361053

Group type: EXPERIMENTAL
Intervention: Linezolid with pseudoephedrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linezolid with phenylpropanolamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linezolid with dextromethorphan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linezolid alone
Number of subjects: 0
Study: 9620567

Group type: EXPERIMENTAL
Intervention: ORS + CBJ
Number of subjects: 80

Group type: COMPARATOR
Intervention: ORS
Number of subjects: 80
Study: 8057000

Group type: EXPERIMENTAL
Intervention: Sertraline (50 or 100 mg/day)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Dothiepin (75 or 150 mg/day)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 3127265

Group type: EXPERIMENTAL
Intervention: Ranitidine (H2 blocker)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Continuous enteral nutrition
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31051499

Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD, 50 E% carbohydrates and 33 E% fat, including 57 g pistachios/d)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pistachio-supplemented diet (PD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Isocaloric control diet (CD, 55 E% carbohydrates and 30 E% fat)
Number of subjects: 49
Study: 27488933

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.45 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.6 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ramosetron (all doses)
Number of subjects: 3
Study: 25556682

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 0
Study: 22496083

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 103
Study: 19808911

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 904

Group type: COMPARATOR
Intervention: Glyburide
Number of subjects: 904

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 904
Study: 17903391

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Valproate (VPS)
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Topiramate (TPM)
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) assessments
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: Health economic analysis
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Health economic assessment for VPS
Number of subjects: 2437
Study: 15652310

Group type: EXPERIMENTAL
Intervention: Brain activity measured during emotional facial expression stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional face stimuli
Number of subjects: 0
Study: 14562597

Group type: COMPARATOR
Intervention: Prostaglandin E2 pessary
Number of subjects: 406

Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 406

Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha gel
Number of subjects: 406
Study: 10544953

Group type: EXPERIMENTAL
Intervention: VLDL from NIDDM patients
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: VLDL from IDDM patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: VLDL and HDL from healthy subjects
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: HDL from NIDDM patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: HDL from healthy subjects
Number of subjects: 43
Study: 7599911

Group type: EXPERIMENTAL
Intervention: Metosil (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Plasil BP (10 mg)
Number of subjects: 18
Study: 2221413

Group type: EXPERIMENTAL
Intervention: 3 g carnitine intravenously before cardiopulmonary bypass (CPB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6 g carnitine intravenously before cardiopulmonary bypass (CPB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 304478

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pentamidine isethionate
Number of subjects: 50
Study: 30798143

Group type: EXPERIMENTAL
Intervention: Parent administered resilience component in conjunction with stuttering therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Fluency therapy only
Number of subjects: 28
Study: 30392386

Group type: EXPERIMENTAL
Intervention: Quantitative structure‐property relationship models using various 2D molecular descriptors derived from single repeating units of polymers.
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Models validated through cross-validation, external validation, Y-randomization test, and applicability domain study.
Number of subjects: 206

Group type: COMPARATOR
Intervention: Comparison with previously published models based on smaller datasets.
Number of subjects: 206